Santander Sube su Apuesta Por Inditex: Sobreponderar, Potencial del 7,8% y Nuevos Máximos en 59€.: Zalypsis ( PM00104 ) showed a positive risk-benefit ratio, which has supported its further evaluation in three ongoing phase II clinical trials.